Radiotherapy versus carboplatin for Stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214)
Reviewer: Arpi Thukral, MD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: June 2, 2008
Presenter: R. T. Oliver
Presenter's Affiliation: St. Bartholomew’s Hospital, London, United Kingdom
Type of Session: Plenary
- Seminonas are the most common subtype of testicular cancers, accounting for about 40% of cases. Stage I seminomas are limited to the testis.
- Since the 1950s, the standard of care for treatment of Stage I seminomas has been orchiectomy followed by adjuvant irradiation of the pelvic and para-aortic notes. The relapse rate for this treatment is nearly 5%.
- However, studies in the 1980’s and 1990’s have shown that patients with adjuvant RT had a 20% excess mortality when compared to matched controls, and randomized trials have shown efficacy of decreased RT exposure.
- It has also been noted that about 80% of these patients are cured by orchiectomy alone, but when stratified by risk factors, there are some patients who can be defined as having an increased risk of relapse.
- Since surveillance is not always an optimal method, and irradiation was found to be associated with a higher risk of mortality, secondary malignancies, and cardiovascular events, the UK Medical Research Council has conducted 2 studies to examine a reduction in the amount of radiation and the extent of the radiation field.
- The TE 10 study compared para-aortic (PA) strip with dog-leg (DL) field irradiation (ie, PA strip plus ipsilateral iliac and inguinal fields) and found a significantly increased rate of pelvic relapse in the PA only group. The TE 18 studied compared 30 Gy vs. 20 Gy for the total dose, and did not see a difference in relapse-free survival (RFS).
- It has also been seen that metastatic seminomas have an increased sensitivity to single agent platinum-based chemotherapy compared with non-seminomas.
- It was thus hypothesized that treatment with carboplatin may be a possible alternative to radiation.
- The present study is a randomized, collaborative trial to compare 1 course of carboplatin with radiotherapy following orchiectomy in stage I seminoma patients. The initial results of this study were presented by the authors at ASCO 2004 with a median follow up on 4 years. The authors are now presenting the updated results with a 6.5 year median follow-up.
Materials and Methods
- Between 1996 and 2001, 1,477 patients with Stage I seminoma s/p orchiectomy were randomized to radiation therapy (RT) at 20-30 Gy (n=904) vs. 1 injection of carboplatin (C).
- C was dosed at 7x(GFR+25) if EDTA was used (n=357) and 90% of this dose if creatinine clearance was used (n=202).
- The randomization was 3C:5RT.
- This study has a non-inferiority design, and is powered to exclude a 3% difference with 90% certainty.
- The primary endpoint was RFS, and this was determined using a Kaplan-Meier method and hazard ratios from the Cox regression model.
- In this update, an analysis of RFS for the variation of dose of C (based on which renal function parameter was used) was also performed, however this was a non-randomized comparison.
- Patient characteristics were balanced and there were no significant differences between the groups.
- Median follow up for this update is 6.5 years, and 78% (n=1148) of patients have a documented minimum 5-year follow up (previously, it was only 23%).
- The RFS rate for the RT group was 96.0% and in the C group was 94.7%, and the HR was 1.25 (0.83, 1.89).
- There was, however, a significant difference in the rate of 2nd primary germ cell tumors (GCT). It was 2 (0.3%) for C and 15 (1.7%) on RT, with a HR of 0.22 (0.05, 0.95), p=0.03.
- When comparing the 2 C doses, no significant difference was seen between the groups (92.6% vs. 96.1%).
- In terms of toxicity, patients were scored based on percentage of patients able to work at 4 weeks and 12 weeks. There was a significant difference at week 4 between C and RT (19% vs. 38%, p<0.05), however this difference was not present at 12 weeks. There was increased grade 2 and 3 thrombocytopenia in the C group compared to the RT group. Other toxicities were not mentioned.
- One course of carboplatin is safe, is less acutely toxic, and is as effective as RT for stage I seminoma.
With longer follow up, this report confirms the previously presented results.
- There is a reduced risk of 2nd GCT in the C arm compared to the RT arm.
- Longer follow up, close to 20 years, is needed to examine death rates from non-germ cell secondary cancers and heart disease between the 2 groups.
- Seminomas are the most common testicular germ cell tumor, and usually affect young men. Although the cure rate is close to 99% in these patients, the risk of relapse and secondary toxicities of treatments are of great concern, since these patients often survive for many years.
- This prospective, randomized non-inferiority trial demonstrates that carboplatin is not less effective than RT as adjuvant treatment for Stage I seminoma. Since this is not a superiority trial, one cannot conclude that one treatment is more effective than the other, but that carboplatin may be an alternative to RT.
- In addition, since the survival rate of these patients is so high, it would not be meaningful to look at differences in overall survival in these patients.
- In terms of the clinical implications of these results, the big question becomes, which alternative should I choose for my patients? The goal when choosing treatments for patients is to maximize cure rate with the least toxicity possible. We need to focus on a relative risk/benefit ratio for the patient population we are treating.
- The authors report that carboplatin was associated with fewer toxic effects and a more rapid return to work than radiotherapy, as well as a reduced incidence of secondary GCTs compared to RT. However, it is unclear how detrimental a secondary GCT is to a patient, since its cure rate is so high. Data on risks of late non-germ cell secondary malignancies and cardiovascular toxicity between the 2 groups would be more beneficial in choosing an optimal therapy. Extended long-term follow-up is needed to determine these risks.
- Based on these results, we should understand that carboplatin is an effective alternative to RT in terms of RFS and is an option.
- However, we do not have enough longer-term follow up data to change our current standard of care of orchiectomy followed by RT.
View Patient Summary
Randomized Controlled HCC Screening Trial Not Feasible
Dec 8, 2011 - A randomized controlled trial of hepatocellular carcinoma (HCC) screening is not feasible for informed patients with cirrhosis; and small HCC detection is not improved by ultrasonographic screening every three versus six months, according to two studies published in the December issue of Hepatology.
Frequently Asked Questions
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!